Erythropoietin in cancer: A dilemma in risk therapy

Trends in Endocrinology and Metabolism

Volumn 24, Issue 4, 2013, Pages 190-199

  Cao, Yihai ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Anemia; Angiogenesis; Cancer therapy; Erythropoiesis; Erythropoietin

Indexed keywords

PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RECOMBINANT ERYTHROPOIETIN; TRASTUZUMAB;

ANEMIA; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL EFFECTIVENESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION;

ANEMIA; ANIMALS; ERYTHROPOIETIN; HUMANS; NEOPLASMS;

EID: 84877921426     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.10.007     Document Type: Review

References (132)

1. Cao Y. Off-tumor target - beneficial site for antiangiogenic cancer therapy?. Nat. Rev. Clin. Oncol. 2010, 7:604-608.
2. Tisdale M.J. Cachexia in cancer patients. Nat. Rev. Cancer 2002, 2:862-871.
3. Fearon K.C. Cancer cachexia and fat-muscle physiology. N. Engl. J. Med. 2011, 365:565-567.
4. Xue Y., et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18513-18518.
5. Costa G., Donaldson S.S. Current concepts in cancer: effects of cancer and cancer treatment on the nutrition of the host. N. Engl. J. Med. 1979, 300:1471-1474.
6. Xue Y., et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat. Med. 2012, 18:100-110.
7. Nguyen M., et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst. 1994, 86:356-361.
8. Kuroi K., Toi M. Circulating angiogenesis regulators in cancer patients. Int. J. Biol. Markers 2001, 16:5-26.
9. Maemura M., et al. Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. Cancer Lett. 1998, 126:215-220.
10. Urba Ska-Rys H., et al. Circulating angiogenic cytokines in multiple myeloma and related disorders. Eur. Cytokine Netw. 2003, 14:40-51.
11. Poon R.T., et al. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003, 63:3121-3126.
12. Blay J.Y., et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992, 52:3317-3322.
13. Digel W., et al. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J. Clin. Invest. 1992, 89:1690-1693.
14. Bargetzi M.J., et al. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res. 1993, 53:4010-4013.
15. Oliff A., et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987, 50:555-563.
16. Todorov P., et al. Characterization of a cancer cachectic factor. Nature 1996, 379:739-742.
17. Tsujinaka T., et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J. Clin. Invest. 1996, 97:244-249.
18. Strassmann G., et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 1992, 89:1681-1684.
19. Fujiki F., et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res. 1997, 57:94-99.
20. Rahbari N.N., et al. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 2011, 11:286.
21. Rahbari N.N., et al. Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann. Surg. Oncol. 2011, 18:2182-2191.
22. Wong A.K., et al. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7481-7486.
23. Cao R., et al. VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:856-861.
24. Zhang D., et al. Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4117-4122.
25. Billingsley K.G., et al. Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann. Surg. Oncol. 1996, 3:29-35.
26. Keller U. Pathophysiology of cancer cachexia. Support. Care Cancer 1993, 1:290-294.
27. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
28. Elliott S., Sinclair A.M. The effect of erythropoietin on normal and neoplastic cells. Biologics 2012, 6:163-189.
29. Koury M.J., Bondurant M.C. The mechanism of erythropoietin action. Am. J. Kidney Dis. 1991, 18:20-23.
30. Eckardt K.U., et al. Age-dependent expression of the erythropoietin gene in rat liver and kidneys. J. Clin. Invest. 1992, 89:753-760.
31. Rankin E.B., et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest. 2007, 117:1068-1077.
32. Erslev A.J., et al. Erythropoietin titers in anemic, nonuremic patients. J. Lab. Clin. Med. 1987, 109:429-433.
33. Eschbach J.W., et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987, 316:73-78.
34. Chateauvieux S., et al. Erythropoietin, erythropoiesis and beyond. Biochem. Pharmacol. 2011, 82:1291-1303.
35. Wojchowski D.M., et al. Erythropoietin receptor response circuits. Curr. Opin. Hematol. 2010, 17:169-176.
36. Heinrich A.C., et al. A mouse model for visualization and conditional mutations in the erythroid lineage. Blood 2004, 104:659-666.
37. Singbrant S., et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood 2011, 117:5631-5642.
38. David R.B., et al. Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus. Mol. Cell. Endocrinol. 2002, 188:207-218.
39. Jeong J.Y., et al. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int. J. Cancer 2008, 122:274-280.
40. Liu Z.Y., et al. Tissue specific expression of human erythropoietin receptor in transgenic mice. Dev. Biol. 1994, 166:159-169.
41. Hardee M.E., et al. Erythropoietin biology in cancer. Clin. Cancer Res. 2006, 12:332-339.
42. Swift S., et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010, 115:4254-4263.
43. Snow J.W., Orkin S.H. Translational isoforms of FOG1 regulate GATA1-interacting complexes. J. Biol. Chem. 2009, 284:29310-29319.
44. Kassouf M.T., et al. Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells. Genome Res. 2010, 20:1064-1083.
45. Remy I., et al. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999, 283:990-993.
46. Glaspy J., et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 2010, 102:301-315.
47. Liang K., et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010, 18:423-435.
48. Osterborg A., et al. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur. J. Cancer 2007, 43:510-519.
49. Szenajch J., et al. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochim. Biophys. Acta 2010, 1806:82-95.
50. Hadland B.K., Longmore G.D. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J. Clin. Oncol. 2009, 27:4217-4226.
51. Jelkmann W., et al. The erythropoietin receptor in normal and cancer tissues. Crit. Rev. Oncol. Hematol. 2008, 67:39-61.
52. Henke M., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.
53. Oster H.S., et al. Erythropoietin: the swinging pendulum. Leuk. Res. 2012, 36:939-944.
54. Miller C.P., et al. Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells 2009, 27:2353-2361.
55. Sartelet H., et al. Expression of erythropoietin and its receptor in neuroblastomas. Cancer 2007, 110:1096-1106.
56. Elliott S., et al. Lack of expression and function of erythropoietin receptors in the kidney. Nephrol. Dial. Transplant. 2012, 27:2733-2745.
57. Kang J.K., et al. Downregulation of erythropoietin receptor by overexpression of phospholipase C-gamma 1 is critical for decrease on focal adhesion in transformed cells. Cell. Oncol. (Dordr.) 2011, 34:11-21.
58. Lai S.Y., et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005, 24:4442-4449.
59. Dunlop E.A., et al. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener. Dis. 2006, 3:94-100.
60. Um M., Lodish H.F. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J. Biol. Chem. 2006, 281:5648-5656.
61. Sinclair A.M., et al. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007, 110:477-488.
62. Sasaki Y., et al. No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo. Acta Oncol. 2009, 48:1062-1069.
63. Ribatti D., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93:2627-2636.
64. Anagnostou A., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:3974-3978.
65. Yamaji R., et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur. J. Biochem. 1996, 239:494-500.
66. Anagnostou A., et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:5978-5982.
67. Ribatti D. Erythropoietin and tumor angiogenesis. Stem Cells Dev. 2010, 19:1-4.
68. Heeschen C., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340-1346.
69. Muller-Ehmsen J., et al. Role of erythropoietin for angiogenesis and vasculogenesis: from embryonic development through adulthood. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H331-H340.
70. Yasuda Y., et al. Expression of erythropoietin in human female reproductive organs. Ital. J. Anat. Embryol. 2001, 106:215-222.
71. Okazaki T., et al. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008, 10:932-939.
72. Yang J., et al. Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis. Int. J. Oncol. 2012, 40:1230-1237.
73. Ribatti D., et al. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 2007, 50:591-596.
74. Ribatti D., et al. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 2007, 50:636-641.
75. Wiesener M.S., et al. Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. Int. J. Cancer 2007, 121:2434-2442.
76. Nico B., et al. Epo is involved in angiogenesis in human glioma. J. Neurooncol. 2011, 102:51-58.
77. Ribatti D., et al. Erythropoietin is involved in angiogenesis in human primary melanoma. Int. J. Exp. Pathol. 2010, 91:495-499.
78. Li M., et al. Expression of erythropoietin receptor in esophageal carcinoma and its correlation to microvessel density. Ai Zheng 2008, 27:52-57. (in Chinese).
79. Li H.G., et al. Prognostic significance of erythropoietin and erythropoietin receptor in tongue squamous cell carcinoma. Br. J. Oral Maxillofac. Surg. 2009, 47:470-475.
80. Hardee M.E., et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007, 2:e549.
81. Perelman N., et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 2003, 102:1506-1514.
82. Nakano M., et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ. Res. 2007, 100:662-669.
83. Grimm C., et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat. Med. 2002, 8:718-724.
84. Cheng J., et al. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007, 131:584-595.
85. Tam B.Y., et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat. Med. 2006, 12:793-800.
86. Carmeliet P., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
87. Makino Y., et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001, 414:550-554.
88. Rankin E.B., et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell 2012, 149:63-74.
89. Minamishima Y.A., Kaelin W.G. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 2010, 329:407.
90. Rouhi P., et al. Hypoxia-induced metastasis model in embryonic zebrafish. Nat. Protoc. 2010, 5:1911-1918.
91. Rouhi P., et al. Pathological angiogenesis facilitates tumor cell dissemination and metastasis. Cell Cycle 2010, 9:913-917.
92. Lee S.L., et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19485-19490.
93. Wincewicz A., et al. STAT3 and hypoxia induced proteins - HIF-1alpha, EPO and EPOR in relation with Bax and Bcl-xL in nodal metastases of ductal breast cancers. Folia Histochem. Cytobiol. 2009, 47:425-430.
94. Rossler J., et al. Hypoxia-induced erythropoietin expression in human neuroblastoma requires a methylation free HIF-1 binding site. J. Cell. Biochem. 2004, 93:153-161.
95. Warnecke C., et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 2004, 18:1462-1464.
96. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2009, 2:re1.
97. Rafii S., Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 2003, 9:702-712.
98. Lyden D., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
99. Sautina L., et al. Induction of nitric oxide by erythropoietin is mediated by the β common receptor and requires interaction with VEGF receptor 2. Blood 2010, 115:896-905.
100. Rad F.H., et al. Novel somatic mutations of the VHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cells. Am. J. Hematol. 2008, 83:155-158.
101. Xue Y., et al. Tumor-derived VEGF modulates hematopoiesis. J. Angiogenes. Res. 2009, 1:9.
102. Wang L., et al. Tumor necrosis factor alpha primes cerebral endothelial cells for erythropoietin-induced angiogenesis. J. Cereb. Blood Flow Metab. 2011, 31:640-647.
103. Taoufik E., et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6185-6190.
104. Bjorndahl M.A., et al. Vascular endothelial growth factor-A promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res. 2005, 65:9261-9268.
105. Lee A.S., et al. Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. Cancer Res. 2011, 71:4506-4517.
106. Patitucci M., et al. Angiogenic/lymphangiogenic factors and adaptation to extreme altitudes during an expedition to Mount Everest. Acta Physiol. (Oxf.) 2009, 196:259-265.
107. Nagy J.A., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 2002, 196:1497-1506.
108. Hong Y.K., et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 2004, 18:1111-1113.
109. Westermark B., Heldin C.H. Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth. Acta Oncol. 1993, 32:101-105.
110. Heldin C.H., et al. Platelet-derived growth factor: isoform-specific signalling via heterodimeric or homodimeric receptor complexes. Kidney Int. 1992, 41:571-574.
111. Andrae J., et al. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22:1276-1312.
112. Nissen L.J., et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 2007, 117:2766-2777.
113. Cao R., et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 2003, 9:604-613.
114. Guo S., et al. PDGFRbeta triggered by bFGF promotes the proliferation, migration of endothelial progenitor cells via p-ERK signaling. Cell Biol. Int. 2012, 36:945-950.
115. Zhang J., et al. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J. 2009, 23:153-163.
116. Cao Y., et al. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J. Mol. Med. (Berl.) 2008, 86:785-789.
117. Spivak J.L. Recombinant human erythropoietin and the anemia of cancer. Blood 1994, 84:997-1004.
118. Ludwig H., et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995, 76:2319-2329.
119. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003, 4:459-460.
120. Bohlius J., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-1542.
121. Tonelli M., et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009, 180:E62-E71.
122. Hedley B.D., et al. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin. Cancer Res. 2011, 17:6373-6380.
123. Hedley B.D., et al. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin. Cancer Res. 2011, 17:6151-6162.
124. Janmaat M.L., et al. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood 2010, 115:1453-1460.
125. Buck I., et al. Linking anemia to inflammation and cancer: the crucial role of TNFalpha. Biochem. Pharmacol. 2009, 77:1572-1579.
126. Newland A.M., Black C.D. Tumor progression associated with erythropoiesis-stimulating agents. Ann. Pharmacother. 2008, 42:1865-1870.
127. Varlotto J., Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:25-36.
128. Dicato M., Plawny L. Erythropoietin in cancer patients: pros and cons. Curr. Opin. Oncol. 2010, 22:307-311.
129. Kertesz N., et al. The role of erythropoietin in regulating angiogenesis. Dev. Biol. 2004, 276:101-110.
130. Lombardero M., et al. Erythropoietin: a hormone with multiple functions. Pathobiology 2011, 78:41-53.
131. Lee R., et al. Erythropoietin (Epo) and EpoR expression and 2 waves of erythropoiesis. Blood 2001, 98:1408-1415.
132. Wu H., et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995, 83:59-67.